On the other hand, the Joint Analysis of the ABC (Anthracyclines in Early Breast Cancer) Trials [USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 (NRG Oncology)], including 2125 patients, comparing (TC) to anthracycline/taxane-based chemotherapy (TaxAC) indicated that the TaxAC regimens improved invasive disease-free survival (IDFS) in patients with high-risk human epidermal growth factor receptor 2-negative BC compared with the IDFS in those with TC6. Here, ERBB2 is linked to breast cancer.